The US FDA said in draft guidance that accurate information comparing a biosimilar and its reference could be considered misleading if offered in the wrong context. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
